Preclinical diagnosis of Alzheimer’s disease. Prevention or prediction?
Fuente:
Redalyc
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artículo científico |
| Sprache: | en |
| Veröffentlicht: |
Associação Neurologia Cognitiva e do Comportamento
2010
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1876444578654978048 |
|---|---|
| author | Ricardo Nitrini |
| author_facet | Ricardo Nitrini |
| contents | Preclinical diagnosis of Alzheimer’s disease. Prevention or prediction? Ricardo Nitrini Medicina biomarkers Alzheimer’s disease preclinical diagnosis The diagnosis of Alzheimer’s disease (AD) for cases with dementia may be too late to allow effective treatment. Criteria for diagnosis of preclinical AD suggested by the Alzheimer’s Association include the use of molecular and structural biomarkers. Preclinical diagnosis will enable testing of new drugs and forms of treatment toward achieving successful preventive treatment. But what are the advantages for the individual? To know that someone who is cognitively normal is probably going to develop AD’s dementia when there is no effective preventive treatment is definitely not good news. A research method whereby volunteers are assigned to receive treatment or placebo without knowing whether they are in the control or at-risk arm of a trial would overcome this potential problem. If these new criteria are used wisely they may represent a relevant milestone in the search for a definitive treatment for AD. 2010 artículo científico 1980-5764 https://www.redalyc.org/articulo.oa?id=339529019002 en http://www.redalyc.org/revista.oa?id=3395 Dementia & Neuropsychologia application/pdf Associação Neurologia Cognitiva e do Comportamento Dementia & Neuropsychologia (Brasil) Num.4 Vol.4 |
| format | Artículo científico |
| id | redalyc_339529019002 |
| institution | Redalyc |
| language | en |
| publishDate | 2010 |
| publisher | Associação Neurologia Cognitiva e do Comportamento |
| spellingShingle | Preclinical diagnosis of Alzheimer’s disease. Prevention or prediction? Ricardo Nitrini Medicina biomarkers Alzheimer’s disease preclinical diagnosis Preclinical diagnosis of Alzheimer’s disease. Prevention or prediction? Ricardo Nitrini Medicina biomarkers Alzheimer’s disease preclinical diagnosis The diagnosis of Alzheimer’s disease (AD) for cases with dementia may be too late to allow effective treatment. Criteria for diagnosis of preclinical AD suggested by the Alzheimer’s Association include the use of molecular and structural biomarkers. Preclinical diagnosis will enable testing of new drugs and forms of treatment toward achieving successful preventive treatment. But what are the advantages for the individual? To know that someone who is cognitively normal is probably going to develop AD’s dementia when there is no effective preventive treatment is definitely not good news. A research method whereby volunteers are assigned to receive treatment or placebo without knowing whether they are in the control or at-risk arm of a trial would overcome this potential problem. If these new criteria are used wisely they may represent a relevant milestone in the search for a definitive treatment for AD. 2010 artículo científico 1980-5764 https://www.redalyc.org/articulo.oa?id=339529019002 en http://www.redalyc.org/revista.oa?id=3395 Dementia & Neuropsychologia application/pdf Associação Neurologia Cognitiva e do Comportamento Dementia & Neuropsychologia (Brasil) Num.4 Vol.4 |
| title | Preclinical diagnosis of Alzheimer’s disease. Prevention or prediction? |
| topic | Medicina biomarkers Alzheimer’s disease preclinical diagnosis |
| url | https://www.redalyc.org/articulo.oa?id=339529019002 |